The role of CD133 in hepatocellular carcinoma

References

• Bruix J, Gores GJ, Mazzaferro V. Hepatocellular carcinoma: clinical frontiers and perspectives. Gut. 2014;63(5):844–855. doi:10.1136/gutjnl-2013-306627.
   PubMed Web of Science ®Google Scholar
• Koren E, Fuchs Y. The bad seed: cancer stem cells in tumor development and resistance. Drug Resist Updat. 2016;28:1–12. doi:10.1016/j.drup.2016.06.006.
   PubMed Web of Science ®Google Scholar
• Yamashita T, Wang XW. Cancer stem cells in the development of liver cancer. J Clin Invest. 2013;123(5):1911–1918. doi:10.1172/JCI66024.
   PubMed Web of Science ®Google Scholar
• Visvader JE, Lindeman GJ. Cancer stem cells in solid tumours: accumulating evidence and unresolved questions. Nat Rev Cancer. 2008;8(10):755–768. doi:10.1038/nrc2499.
   PubMed Web of Science ®Google Scholar
• Nio K, Yamashita T, Kaneko S. The evolving concept of liver cancer stem cells. Mol Cancer. 2017;16(1):4. doi:10.1186/s12943-016-0572-9.
   PubMed Web of Science ®Google Scholar
• Wang NZ, Wang SS, Li MY, Hu BG, Liu LP, Yang SL, Yang SC, Gong ZQ, Lai PBS, Chen GG. Cancer stem cells in hepatocellular carcinoma: an overview and promising therapeutic strategies. Ther Adv Med Oncol. 2018;10:1758835918816287. doi:10.1177/1758835918816287.
   Web of Science ®Google Scholar
• Glumac PM, LeBeau AM. The role of CD133 in cancer: a concise review. Clin Transl Med. 2018;7(1):18. doi:10.1186/s40169-018-0198-1.
   PubMed Web of Science ®Google Scholar
• Suetsugu A, Nagaki M, Aoki H, Motohashi T, Kunisada T, Moriwaki H. Characterization of CD133+ hepatocellular carcinoma cells as cancer stem/progenitor cells. Biochem Biophys Res Commun. 2006;351(4):820–824. doi:10.1016/j.bbrc.2006.10.128.
   PubMed Web of Science ®Google Scholar
• Ma S, Chan KW, Hu L, Lee TK, Wo JY, Ng IO, Zheng BJ, Guan XY. Identification and characterization of tumorigenic liver cancer stem/progenitor cells. Gastroenterology. 2007;132(7):2542–2556. doi:10.1053/j.gastro.2007.04.025.
   PubMed Web of Science ®Google Scholar
• Yin SY, Li JJ, Hu C, Chen XH, Yao M, Yan MX, Jiang GP, Ge C, Xie HY, Wan DF, et al. CD133 positive hepatocellular carcinoma cells possess high capacity for tumorigenicity. Int J Cancer. 2007;120(7):1444–1450. DOI:10.1002/ijc.22476
   PubMed Web of Science ®Google Scholar
• Corbeil D, Röper K, Fargeas CA, Joester A, Huttner WB. Prominin: a story of cholesterol, plasma membrane protrusions and human pathology. Traffic. 2001;2(2):82–91. doi:10.1034/j.1600-0854.2001.020202.x.
   PubMed Web of Science ®Google Scholar
• Corbeil D, Karbanová J, Fargeas CA, Jászai J. Prominin-1 (CD133): molecular and cellular features across species. Adv Exp Med Biol. 2013;777:3–24. doi:10.1007/978-1-4614-5894-4_1.
   PubMed Web of Science ®Google Scholar
• Jang JW, Song Y, Kim SH, Kim J-S, Kim KM, Choi EK, Kim J, Seo HR. CD133 confers cancer stem-like cell properties by stabilizing EGFR-AKT signaling in hepatocellular carcinoma. Cancer Lett. 2017;389:1–10. doi:10.1016/j.canlet.2016.12.023.
   PubMed Web of Science ®Google Scholar
• Kim S, Cho CY, Lee D, Song DG, Kim HJ, Jun JW, Kim JE, Park D, Lee H, Um H, et al. CD133-induced TM4SF5 expression promotes sphere growth via recruitment and blocking of protein tyrosine phosphatase receptor type F (PTPRF). Cancer Lett. 2018;438:219–231. doi:10.1016/j.canlet.2018.09.009.
   PubMed Web of Science ®Google Scholar
• Lee SH, Hyun SK, Kim HB, Kang CD, Kim SH. Potential role of CD133 expression in the susceptibility of human liver cancer stem-like cells to TRAIL. Oncol Res. 2016;24(6):495–509. doi:10.3727/096504016x14685034103950.
   PubMed Web of Science ®Google Scholar
• Kohga K, Tatsumi T, Takehara T, Tsunematsu H, Shimizu S, Yamamoto M, Sasakawa A, Miyagi T, Hayashi N, et al. Expression of CD133 confers malignant potential by regulating metalloproteinases in human hepatocellular carcinoma. J Hepatol. 2010;52(6):872–879. DOI:10.1016/j.jhep.2009.12.030
   PubMed Web of Science ®Google Scholar
• Kang M, Kim S, Ko J. Roles of CD133 in microvesicle formation and oncoprotein trafficking in colon cancer. FASEB J. 2019;33(3):4248–4260. doi:10.1096/fj.201802018R.
   PubMed Web of Science ®Google Scholar
• Karbanová J, Laco J, Marzesco AM, Janich P, Voborníková M, Mokrý J, Fargeas CA, Huttner WB, Corbeil D, et al. Human prominin-1 (CD133) is detected in both neoplastic and non-neoplastic salivary gland diseases and released into saliva in a ubiquitinated form. PloS One. 2014;9(6):e98927. DOI:10.1371/journal.pone.0098927
   PubMed Web of Science ®Google Scholar
• Chen HY, Luo ZL, Dong LW, Tan YX, Yang JM, Feng GH, Wu MC, Li Z, Wang HY. CD133/prominin-1-mediated autophagy and glucose uptake beneficial for hepatoma cell survival. PloS One. 2013;8(2):e56878. DOI:10.1371/journal.pone.0056878
   PubMed Web of Science ®Google Scholar
• Tang KH, Ma S, Lee TK, Chan YP, Kwan PS, Tong CM, Ng IO, Man K, To KF, Lai PB, et al. CD133(+) liver tumor-initiating cells promote tumor angiogenesis, growth, and self-renewal through neurotensin/interleukin-8/CXCL1 signaling. Hepatology. 2012;55(3):807–820. DOI:10.1002/hep.24739
   PubMed Web of Science ®Google Scholar
• Jin YL, Mao J, Wang HX, Hou ZH, Ma W, Zhang J, Wang B, Huang YH, Zang SZ, Tang JW, et al. Enhanced tumorigenesis and lymphatic metastasis of CD133+ hepatocarcinoma ascites syngeneic cell lines mediated by JNK signaling pathway in vitro and in vivo. Biomed Pharmacother. 2013;67(4):337–345. DOI:10.1016/j.biopha.2013.02.006
   PubMed Web of Science ®Google Scholar
• Na DC, Lee JE, Yoo JE, Oh BK, Choi GH, Park YN. Invasion and EMT-associated genes are up-regulated in B viral hepatocellular carcinoma with high expression of CD133-human and cell culture study. Exp Mol Pathol. 2011;90(1):66–73. doi:10.1016/j.yexmp.2010.10.003.
   PubMed Web of Science ®Google Scholar
• Xu YX, Lai Y, Weng HQ, Tan LP, Li YS, Chen GC, Luo XX, Ye YB, et al. MiR-124 sensitizes cisplatin-induced cytotoxicity against CD133(+) hepatocellular carcinoma cells by targeting SIRT1/ROS/JNK pathway. Aging. 2019;11(9):2551–2564. DOI:10.18632/aging.101876
   PubMedGoogle Scholar
• Ma S, Lee TK, Zheng BJ, Chan KW, Guan XY. CD133+ HCC cancer stem cells confer chemoresistance by preferential expression of the Akt/PKB survival pathway. Oncogene. 2008;27(12):1749–1758. doi:10.1038/sj.onc.1210811.
   PubMed Web of Science ®Google Scholar
• Hemati H, Kaur J, Sobti RC, Trehanpati N. Inhibition of NOTCH signaling pathway chemosensitizes HCC CD133(+) cells to vincristine and 5-fluorouracil through upregulation of BBC3. Biochem Biophys Res Commun. 2020;525(4):941–947. doi:10.1016/j.bbrc.2020.03.009.
   PubMed Web of Science ®Google Scholar
• Kahraman DC, Kahraman T, Cetin-Atalay R. Targeting PI3K/Akt/mTOR pathway identifies differential expression and functional role of IL8 in liver cancer stem cell enrichment. Mol Cancer Ther. 2019;18(11):2146–2157. doi:10.1158/1535-7163.Mct-19-0004.
   PubMed Web of Science ®Google Scholar
• Piao LS, Hur W, Kim TK, Hong SW, Kim SW, Choi JE, Sung PS, Song MJ, Lee BC, Hwang D, et al. CD133+ liver cancer stem cells modulate radioresistance in human hepatocellular carcinoma. Cancer Lett. 2012;315(2):129–137. DOI:10.1016/j.canlet.2011.10.012
   PubMed Web of Science ®Google Scholar
• Lee YK, Hur W, Lee SW, Hong SW, Kim SW, Choi JE, Yoon SK. Knockdown of 14-3-3ζ enhances radiosensitivity and radio-induced apoptosis in CD133(+) liver cancer stem cells. Exp Mol Med. 2014;46(2):e77. doi:10.1038/emm.2013.151.
   PubMedGoogle Scholar
• Hong SW, Hur W, Choi JE, Kim JH, Hwang D, Yoon SK. Role of ADAM17 in invasion and migration of CD133-expressing liver cancer stem cells after irradiation. 2016;Oncotarget. 7(17):23482–23497. doi:10.18632/oncotarget.8112.
   PubMedGoogle Scholar
• Liberti MV, Locasale JW. The Warburg effect: how does it benefit cancer cells? Trends Biochem Sci. 2016;41(3):211–218. doi:10.1016/j.tibs.2015.12.001.
   PubMed Web of Science ®Google Scholar
• Zhang HL, Wang MD, Zhou X, Qin CJ, Fu GB, Tang L, Wu H, Huang S, Zhao LH, Zeng M, et al. Blocking preferential glucose uptake sensitizes liver tumor-initiating cells to glucose restriction and sorafenib treatment. Cancer Lett. 2017;388:1–11. doi:10.1016/j.canlet.2016.11.023.
   PubMed Web of Science ®Google Scholar
• El Hout M, Cosialls E, Mehrpour M, Hamaï A. Crosstalk between autophagy and metabolic regulation of cancer stem cells. Mol Cancer. 2020;19(1):27. doi:10.1186/s12943-019-1126-8.
   PubMed Web of Science ®Google Scholar
• Song YJ, Zhang SS, Guo XL, Sun K, Han ZP, Li R, Zhao QD, Deng WJ, Xie XQ, Zhang JW, et al. Autophagy contributes to the survival of CD133+ liver cancer stem cells in the hypoxic and nutrient-deprived tumor microenvironment. Cancer Lett. 2013;339(1):70–81. DOI:10.1016/j.canlet.2013.07.021
   PubMed Web of Science ®Google Scholar
• Salnikov AV, Kusumawidjaja G, Rausch V, Bruns H, Gross W, Khamidjanov A, Ryschich E, Gebhard MM, Moldenhauer G, Büchler MW, et al. Cancer stem cell marker expression in hepatocellular carcinoma and liver metastases is not sufficient as single prognostic parameter. Cancer Lett. 2009;275(2):185–193. DOI:10.1016/j.canlet.2008.10.015
   PubMed Web of Science ®Google Scholar
• Ma S, Chan KW, Lee TK, Tang KH, Wo JY, Zheng BJ, Guan XY. Aldehyde dehydrogenase discriminates the CD133 liver cancer stem cell populations. Mol Cancer Res. 2008;6(7):1146–1153. doi:10.1158/1541-7786.Mcr-08-0035.
   PubMed Web of Science ®Google Scholar
• Zheng H, Pomyen Y, Hernandez MO, Li C, Livak F, Tang W, Dang H, Greten TF, Davis JL, Zhao Y, et al. Single-cell analysis reveals cancer stem cell heterogeneity in hepatocellular carcinoma. Hepatology. 2018;68(1):127–140. DOI:10.1002/hep.29778
   PubMed Web of Science ®Google Scholar
• Wu JY, Zhu PP, Lu TK, Du Y, Wang YY, He LY, Ye BQ, Liu BY, Yang LL, Wang J, et al. The long non-coding RNA LncHDAC2 drives the self-renewal of liver cancer stem cells via activation of Hedgehog signaling. J Hepatol. 2019;70(5):918–929. DOI:10.1016/j.jhep.2018.12.015
   PubMed Web of Science ®Google Scholar
• Wang YY, He L, Du Y, Zhu PP, Huang GL, Luo JJ, Yan XL, Ye BQ, Li C, Xia PY, et al. The long noncoding RNA lncTCF7 promotes self-renewal of human liver cancer stem cells through activation of Wnt signaling. Cell Stem Cell. 2015;16(4):413–425. DOI:10.1016/j.stem.2015.03.003
   PubMed Web of Science ®Google Scholar
• Zhu Z, Hao XF, Yan MX, Yao M, Ge C, Gu JR, Li JJ. Cancer stem/progenitor cells are highly enriched in CD133+CD44+ population in hepatocellular carcinoma. Int J Cancer. 2010;126(9):2067–2078. doi:10.1002/ijc.24868.
   PubMed Web of Science ®Google Scholar
• Hou Y, Zou QF, Ge RL, Shen F, Wang YZ. The critical role of CD133(+)CD44(+/high) tumor cells in hematogenous metastasis of liver cancers. Cell Res. 2012;22(1):259–272. doi:10.1038/cr.2011.139.
   PubMed Web of Science ®Google Scholar
• Lee JH, Hur W, Hong SW, Kim JH, Kim SM, Lee EB, Yoon SK. ELK3 promotes the migration and invasion of liver cancer stem cells by targeting HIF-1α. Oncol Rep. 2017;37(2):813–822. doi:10.3892/or.2016.5293.
   PubMed Web of Science ®Google Scholar
• Gao XM, Sheng YY, Yang J, Wang CQ, Zhang R, Zhu Y, Zhang Z, Zhang KL, Yan SC, Sun HT, et al. Osteopontin alters DNA methylation through up-regulating DNMT1 and sensitizes CD133+/CD44+ cancer stem cells to 5 azacytidine in hepatocellular carcinoma. J Exp Clin Cancer Res. 2018;37(1):179. DOI:10.1186/s13046-018-0832-1
   PubMedGoogle Scholar
• Chen Y, Yu DK, Zhang H, He HW, Zhang CX, Zhao WL, Shao RG. CD133(+)EpCAM(+) phenotype possesses more characteristics of tumor initiating cells in hepatocellular carcinoma Huh7 cells. Int J Biol Sci. 2012;8(7):992–1004. doi:10.7150/ijbs.4454.
   PubMed Web of Science ®Google Scholar
• Firtina Karagonlar Z, Koç D, Şahin E, Avci ST, Yilmaz M, Atabey N, Erdal E. Effect of adipocyte-secreted factors on EpCAM+/CD133+ hepatic stem cell population. Biochem Biophys Res Commun. 2016;474(3):482–490. doi:10.1016/j.bbrc.2016.04.137.
   PubMed Web of Science ®Google Scholar
• Delman M, Avcı ST, Akçok İ, Kanbur T, Erdal E, Çağır A. Antiproliferative activity of (R)-4ʹ-methylklavuzon on hepatocellular carcinoma cells and EpCAM(+)/CD133(+) cancer stem cells via SIRT1 and Exportin-1 (CRM1) inhibition. Eur J Med Chem. 2019;180:224–237. doi:10.1016/j.ejmech.2019.07.024.
   PubMed Web of Science ®Google Scholar
• Karagonlar ZF, Akbari S, Karabicici M, Sahin E, Avci ST, Ersoy N, Ates KE, Balli T, Karacicek B, Kaplan KN, et al. A novel function for KLF4 in modulating the de-differentiation of EpCAM(-)/CD133(-) nonStem cells into EpCAM(+)/CD133(+) liver cancer stem cells in HCC cell line HuH7. Cells. 2020;9(5):1198. DOI:10.3390/cells9051198
   PubMed Web of Science ®Google Scholar
• Wang RH, Li YW, Tsung A, Huang H, Du Q, Yang MQ, Deng MH, Xiong S, Wang XJ, Zhang LY, et al. iNOS promotes CD24(+)CD133(+) liver cancer stem cell phenotype through a TACE/ADAM17-dependent Notch signaling pathway. Proc Natl Acad Sci U S A. 2018;115(43):E10127–e36. DOI:10.1073/pnas.1722100115
   PubMed Web of Science ®Google Scholar
• Chai S, Ng KY, Tong M, Lau EY, Lee TK, Chan KW, Yuan YF, Cheung TT, Wang XQ, Wong N, et al. Octamer 4/microRNA-1246 signaling axis drives Wnt/β-catenin activation in liver cancer stem cells. Hepatology. 2016;64(6):2062–2076. DOI:10.1002/hep.28821
   PubMed Web of Science ®Google Scholar
• Hou J, Zhao NP, Zhu PX, Chang J, Du Y, Shen W. Irradiated mesenchymal stem cells support stemness maintenance of hepatocellular carcinoma stem cells through Wnt/β-catenin signaling pathway. Cell Biosci. 2020;10:93. doi:10.1186/s13578-020-00449-5.
   PubMed Web of Science ®Google Scholar
• Rinkenbaugh AL, Baldwin AS. The NF-κB pathway and cancer stem cells. Cells. 2016;5(2):16. doi:10.3390/cells5020016.
   PubMed Web of Science ®Google Scholar
• Ma DQ, Zhang YH, Ding DP, Li J, Chen LL, Tian YY, Ao KJ. Effect of Bmi-1-mediated NF-κB signaling pathway on the stem-like properties of CD133+ human liver cancer cells. Cancer Biomark. 2018;22(3):575–585. doi:10.3233/cbm-181329.
   PubMed Web of Science ®Google Scholar
• Lai FB, Liu WT, Jing YY, Yu GF, Han ZP, Yang X, Zeng JX, Zhang HJ, Shi RY, Li XX, et al. Lipopolysaccharide supports maintaining the stemness of CD133(+) hepatoma cells through activation of the NF-κB/HIF-1α pathway. Cancer Lett. 2016;378(2):131–141. DOI:10.1016/j.canlet.2016.05.014
   PubMed Web of Science ®Google Scholar
• Won C, Kim BH, Yi EH, Choi KJ, Kim EK, Jeong JM, Lee JH, Jang JJ, Yoon JH, Jeong WI, et al. Signal transducer and activator of transcription 3-mediated CD133 up-regulation contributes to promotion of hepatocellular carcinoma. Hepatology. 2015;62(4):1160–1173. DOI:10.1002/hep.27968
   PubMed Web of Science ®Google Scholar
• Wang YW, Wu G, Fu XY, Xu SL, Wang TL, Zhang Q, Yang Y. Aquaporin 3 maintains the stemness of CD133+ hepatocellular carcinoma cells by activating STAT3. Cell Death Dis. 2019;10(6):465. doi:10.1038/s41419-019-1712-0.
   PubMedGoogle Scholar
• Maehara O, Ohnishi S, Asano A, Suda G, Natsuizaka M, Nakagawa K, Kobayashi M, Sakamoto N, Takeda H. Metformin regulates the expression of CD133 through the AMPK-CEBPβ pathway in hepatocellular carcinoma cell lines. Neoplasia. 2019;21(6):545–556. DOI:10.1016/j.neo.2019.03.007
   PubMed Web of Science ®Google Scholar
• Semba T, Sammons R, Wang XP, Xie XM, Dalby KN, Ueno NT. JNK signaling in stem cell self-renewal and differentiation. Int J Mol Sci. 2020;21(7):2613. doi:10.3390/ijms21072613.
   PubMed Web of Science ®Google Scholar
• Tong M, Fung TM, Luk ST, Ng KY, Lee TK, Lin CH, Yam JW, Chan KW, Ng F, Zheng BJ, et al. ANXA3/JNK signaling promotes self-renewal and tumor growth, and its blockade provides a therapeutic target for hepatocellular carcinoma. Stem Cell Rep. 2015;5(1):45–59. DOI:10.1016/j.stemcr.2015.05.013
   PubMed Web of Science ®Google Scholar
• Rawal P, Siddiqui H, Hassan M, Choudhary MC, Tripathi DM, Nain V, Trehanpati N, Kaur S. Endothelial cell-derived TGF-β promotes epithelial-mesenchymal transition via CD133 in HBx-infected hepatoma cells. Front Oncol. 2019;9:308. doi:10.3389/fonc.2019.00308.
   PubMed Web of Science ®Google Scholar
• Liu FC, Kong X, Lv L, Gao J. TGF-β1 acts through miR-155 to down-regulate TP53INP1 in promoting epithelial-mesenchymal transition and cancer stem cell phenotypes. Cancer Lett. 2015;359(2):288–298. doi:10.1016/j.canlet.2015.01.030.
   PubMed Web of Science ®Google Scholar
• Chen GL, Ye T, Chen HL, Zhao ZY, Tang WQ, Wang LS, Xia JL. Xanthine dehydrogenase downregulation promotes TGFβ signaling and cancer stem cell-related gene expression in hepatocellular carcinoma. Oncogenesis. 2017;6(9):e382. doi:10.1038/oncsis.2017.81.
   PubMedGoogle Scholar
• You H, Ding W, Rountree CB. Epigenetic regulation of cancer stem cell marker CD133 by transforming growth factor-beta. Hepatology. 2010;51(5):1635–1644. doi:10.1002/hep.23544.
   PubMed Web of Science ®Google Scholar
• Chen CL, Tsukamoto H, Liu JC, Kashiwabara C, Feldman D, Sher L, Dooley S, French SW, Mishra L, Petrovic L, et al. Reciprocal regulation by TLR4 and TGF-β in tumor-initiating stem-like cells. J Clin Invest. 2013;123(7):2832–2849. DOI:10.1172/jci65859
   PubMed Web of Science ®Google Scholar
• Ran RZ, Chen J, Cui LJ, Lin XL, Fan MM, Cong ZZ, Zhang H, Tan WF, Zhang GQ, Zhang YJ. miR-194 inhibits liver cancer stem cell expansion by regulating RAC1 pathway. Exp Cell Res. 2019;378(1):66–75. doi:10.1016/j.yexcr.2019.03.007.
   PubMed Web of Science ®Google Scholar
• Bai HY, Liao YJ, Cai MY, Ma NF, Zhang Q, Chen JW, Zhang JX, Wang FW, Wang CY, Chen WH, et al. Eukaryotic initiation factor 5A2 contributes to the maintenance of CD133(+) hepatocellular carcinoma cells via the c-Myc/microRNA-29b axis. Stem Cells. 2018;36(2):180–191. DOI:10.1002/stem.2734
   PubMed Web of Science ®Google Scholar
• Ma S, Tang KH, Chan YP, Lee TK, Kwan PS, Castilho A, Ng I, Man K, Wong N, To KF, et al. miR-130b promotes CD133(+) liver tumor-initiating cell growth and self-renewal via tumor protein 53-induced nuclear protein 1. Cell Stem Cell. 2010;7(6):694–707. DOI:10.1016/j.stem.2010.11.010
   PubMed Web of Science ®Google Scholar
• Liu FC, Kong X, Lv L, Gao J. MiR-155 targets TP53INP1 to regulate liver cancer stem cell acquisition and self-renewal. FEBS Lett. 2015;589(4):500–506. doi:10.1016/j.febslet.2015.01.009.
   PubMed Web of Science ®Google Scholar
• Ma S, Cheng JP, Wang HY, Ding NL, Zhou F, Ji RN, Zhu L, Zhu CW, Pan YZ. A novel regulatory loop miR-101/ANXA2/EGR1 mediates malignant characteristics of liver cancer stem cells. Carcinogenesis. 2021;42(1):93–104. doi:10.1093/carcin/bgaa055.
   PubMed Web of Science ®Google Scholar
• Cao XC, Liu LH, Cao XZ, Cui YH, Zou C, Chen A, Qiu YB, Quan MF, Ren KQ, Chen XD, et al. The DNMT1/miR-34a/FOXM1 axis contributes to stemness of liver cancer cells. J Oncol. 2020;2020:8978930. doi:10.1155/2020/8978930.
   PubMed Web of Science ®Google Scholar
• Fu XM, Zhu XY, Qin FJ, Zhang Y, Lin JZ, Ding YC, Yang ZH, Shang YM, Wang L, Zhang QX, et al. Linc00210 drives Wnt/β-catenin signaling activation and liver tumor progression through CTNNBIP1-dependent manner. Mol Cancer. 2018;17(1):73. DOI:10.1186/s12943-018-0783-3
   PubMed Web of Science ®Google Scholar
• Yang C, Cai WC, Dong ZT, Guo JW, Zhao YJ, Sui CJ, Yang JM. lncARSR promotes liver cancer stem cells expansion via STAT3 pathway. Gene. 2019;687:73–81. doi:10.1016/j.gene.2018.10.087.
   PubMed Web of Science ®Google Scholar
• Huang GQ, Jiang H, Lin Y, Xia WZ, Luo YW, Wu YP, Cai WL, Zhou XK, Jiang XH. LncGPR107 drives the self-renewal of liver tumor initiating cells and liver tumorigenesis through GPR107-dependent manner. J Exp Clin Cancer Res. 2018;37(1):121. DOI:10.1186/s13046-018-0794-3
   PubMedGoogle Scholar
• Guo JC, Yang YJ, Zheng JF, Zhang JQ, Guo M, Yang X, Jiang XL, Xiang L, Li Y, Ping H, et al. Silencing of long noncoding RNA HOXA11-AS inhibits the Wnt signaling pathway via the upregulation of HOXA11 and thereby inhibits the proliferation, invasion, and self-renewal of hepatocellular carcinoma stem cells. Exp Mol Med. 2019;51(11):1–20. DOI:10.1038/s12276-019-0328-x
   Google Scholar
• Chang HL, Bamodu OA, Ong JR, Lee WH, Yeh CT, Tsai JT. Targeting the epigenetic non-coding RNA MALAT1/Wnt signaling axis as a therapeutic approach to suppress stemness and metastasis in hepatocellular carcinoma. Cells. 2020;9(4):1020. doi:10.3390/cells9041020.
   PubMed Web of Science ®Google Scholar
• Cheng Z, Li XF, Ding J. Characteristics of liver cancer stem cells and clinical correlations. Cancer Lett. 2016;379(2):230–238. doi:10.1016/j.canlet.2015.07.041.
   PubMed Web of Science ®Google Scholar
• Liu K, Hao MJ, Ouyang Y, Zheng JS, Chen DX. CD133(+) cancer stem cells promoted by VEGF accelerate the recurrence of hepatocellular carcinoma. Sci Rep. 2017;7:41499. doi:10.1038/srep41499.
   PubMed Web of Science ®Google Scholar
• Zhang L, Zhang LX, Li H, Ge C, Zhao FY, Tian H, Chen TY, Jiang GP, Xie HY, Cui Y, et al. CXCL3 contributes to CD133(+) CSCs maintenance and forms a positive feedback regulation loop with CD133 in HCC via Erk1/2 phosphorylation. Sci Rep. 2016;6:27426. doi:10.1038/srep27426.
   PubMed Web of Science ®Google Scholar
• Mitra A, Yan J, Xia XQ, Zhou SH, Chen J, Mishra L, Li SL. IL6-mediated inflammatory loop reprograms normal to epithelial-mesenchymal transition(+) metastatic cancer stem cells in preneoplastic liver of transforming growth factor beta-deficient β2-spectrin(±) mice. Hepatology. 2017;65(4):1222–1236. doi:10.1002/hep.28951.
   PubMed Web of Science ®Google Scholar
• Wei YY, Shi DF, Liang ZW, Liu YM, Li YN, Xing Y, Liu WT, Ai ZL, Jiang JH, Chen XN, et al. IL-17A secreted from lymphatic endothelial cells promotes tumorigenesis by upregulation of PD-L1 in hepatoma stem cells. J Hepatol. 2019;71(6):1206–1215. DOI:10.1016/j.jhep.2019.08.034
   PubMed Web of Science ®Google Scholar
• Chen YL, Lin PY, Ming YZ, Huang WC, Chen RF, Chen PM, Chu PY. The effects of the location of cancer stem cell marker CD133 on the prognosis of hepatocellular carcinoma patients. BMC Cancer. 2017;17(1):474. doi:10.1186/s12885-017-3460-9.
   PubMedGoogle Scholar
• Sasaki A, Kamiyama T, Yokoo H, Nakanishi K, Kubota K, Haga H, Matsushita M, Ozaki M, Matsuno Y, Todo S. Cytoplasmic expression of CD133 is an important risk factor for overall survival in hepatocellular carcinoma. Oncol Rep. 2010;24(2):537–546. doi:10.3892/or_00000890.
   PubMed Web of Science ®Google Scholar
• Song W, Li H, Tao K, Li R, Song Z, Zhao Q, Zhang F, Dou K. Expression and clinical significance of the stem cell marker CD133 in hepatocellular carcinoma. Int J Clin Pract. 2008;62(8):1212–1218. doi:10.1111/j.1742-1241.2008.01777.x.
   PubMed Web of Science ®Google Scholar
• Yu HJ, Zhu XQ, Lin HC, Pan HY, Zhao FY, Zhu MX, Sun L, Chai WJ, Yao M, Yan MX. A new risk model comprising genes highly correlated with CD133 identifies different tumor-immune microenvironment subtypes impacting prognosis in hepatocellular carcinoma. Aging. 2020;12(12):12234–12250. doi:10.18632/aging.103409.
   PubMedGoogle Scholar
• Chan AW, Tong JH, Chan SL, Lai PB, To KF. Expression of stemness markers (CD133 and EpCAM) in prognostication of hepatocellular carcinoma. Histopathology. 2014;64(7):935–950. doi:10.1111/his.12342.
   PubMed Web of Science ®Google Scholar
• Yang XR, Xu Y, Yu B, Zhou J, Qiu SJ, Shi GM, Zhang BH, Wu WZ, Shi YH, Wu B, et al. High expression levels of putative hepatic stem/progenitor cell biomarkers related to tumour angiogenesis and poor prognosis of hepatocellular carcinoma. Gut. 2010;59(7):953–962. DOI:10.1136/gut.2008.176271
   PubMed Web of Science ®Google Scholar
• Dai XM, Yang SL, Zheng XM, Chen GG, Chen J, Zhang T. CD133 expression and α-fetoprotein levels define novel prognostic subtypes of HBV-associated hepatocellular carcinoma: a long-term follow-up analysis. Oncol Lett. 2018;15(3):2985–2991. doi:10.3892/ol.2017.7704.
   PubMed Web of Science ®Google Scholar
• Chen D, Li Z, Cheng Q, Wang Y, Qian L, Gao J, Zhu JY. Genetic alterations and expression of PTEN and its relationship with cancer stem cell markers to investigate pathogenesis and to evaluate prognosis in hepatocellular carcinoma. J Clin Pathol. 2019;72(9):588–596. doi:10.1136/jclinpath-2019-205769.
   PubMed Web of Science ®Google Scholar
• Su RJ, Nan HC, Guo H, Ruan ZP, Jiang LL, Song YY, Nan KJ. Associations of components of PTEN/AKT/mTOR pathway with cancer stem cell markers and prognostic value of these biomarkers in hepatocellular carcinoma. Hepatol Res. 2016;46(13):1380–1391. doi:10.1111/hepr.12687.
   PubMed Web of Science ®Google Scholar
• Hagiwara S, Kudo M, Nagai T, Inoue T, Ueshima K, Nishida N, Watanabe T, Sakurai T. Activation of JNK and high expression level of CD133 predict a poor response to sorafenib in hepatocellular carcinoma. Br J Cancer. 2012;106(12):1997–2003. doi:10.1038/bjc.2012.145.
   PubMed Web of Science ®Google Scholar
• Kim BH, Park JW, Kim JS, Lee SK, Hong EK. Stem cell markers predict the response to sorafenib in patients with hepatocellular carcinoma. Gut Liver. 2019;13(3):342–348. doi:10.5009/gnl18345.
   PubMed Web of Science ®Google Scholar
• Zen C, Zen Y, Mitry RR, Corbeil D, Karbanová J, O’Grady J, Karani J, Kane P, Heaton N, Portmann BC, et al. Mixed phenotype hepatocellular carcinoma after transarterial chemoembolization and liver transplantation. Liver Transpl. 2011;17(8):943–954. DOI:10.1002/lt.22314
   PubMed Web of Science ®Google Scholar
• Vilchez V, Turcios L, Zaytseva Y, Stewart R, Lee EY, Maynard E, Shah MB, Daily MF, Tzeng CWD, Davenport D, et al. Cancer stem cell marker expression alone and in combination with microvascular invasion predicts poor prognosis in patients undergoing transplantation for hepatocellular carcinoma. Am J Surg. 2016;212(2):238–245. DOI:10.1016/j.amjsurg.2015.12.019
   PubMed Web of Science ®Google Scholar
• Chen HY, Luo ZL, Sun W, Zhang CZ, Sun HL, Zhao NJ, Ding J, Wu MC, Li Z, Wang HY. Low glucose promotes CD133mAb-elicited cell death via inhibition of autophagy in hepatocarcinoma cells. Cancer Lett. 2013;336(1):204–212. doi:10.1016/j.canlet.2013.04.031.
   PubMed Web of Science ®Google Scholar
• Marcucci F, Caserta CA, Romeo E, Rumio C. Antibody-drug conjugates (ADC) against cancer stem-like cells (CSC)—is there still room for optimism? Front Oncol. 2019;9:167. doi:10.3389/fonc.2019.00167.
   PubMed Web of Science ®Google Scholar
• Smith LM, Nesterova A, Ryan MC, Duniho S, Jonas M, Anderson M, Zabinski RF, Sutherland MK, Gerber HP, Orden KLV, et al. CD133/prominin-1 is a potential therapeutic target for antibody-drug conjugates in hepatocellular and gastric cancers. Br J Cancer. 2008;99(1):100–109. DOI:10.1038/sj.bjc.6604437
   PubMed Web of Science ®Google Scholar
• Ma HT, Liu JP, Ali MM, Mahmood MA, Labanieh L, Lu MR, Iqbal SM, Zhang Q, Zhao WA, Wan YA. Nucleic acid aptamers in cancer research, diagnosis and therapy. Chem Soc Rev. 2015;44(5):1240–1256. doi:10.1039/c4cs00357h.
   PubMed Web of Science ®Google Scholar
• Jiang JX, Chen HW, Yu C, Zhang YY, Chen MY, Tian S, Sun CY. The promotion of salinomycin delivery to hepatocellular carcinoma cells through EGFR and CD133 aptamers conjugation by PLGA nanoparticles. Nanomedicine. 2015;10(12):1863–1879. doi:10.2217/nnm.15.43.
   PubMed Web of Science ®Google Scholar
• Zhou G, Da Won Bae S, Nguyen R, Huo XQ, Han SL, Zhang ZQ, Hebbard L, Duan W, Eslam M, Liddle C, et al.. An aptamer-based drug delivery agent (CD133-apt-Dox) selectively and effectively kills liver cancer stem-like cells. Cancer Lett. 2021;501:124–132. doi:10.1016/j.canlet.2020.12.022.
   PubMed Web of Science ®Google Scholar
• Labanieh L, Majzner RG, Mackall CL. Programming CAR-T cells to kill cancer. Nat Biomed Eng. 2018;2(6):377–391. doi:10.1038/s41551-018-0235-9.
   PubMed Web of Science ®Google Scholar
• Wang Y, Chen MX, Wu ZQ, Tong C, Dai HR, Guo YL, Liu Y, Huang JH, Lv HY, Luo C, et al.. CD133-directed CAR T cells for advanced metastasis malignancies: a phase I trial. Oncoimmunology. 2018;7(7):e1440169. DOI:10.1080/2162402x.2018.1440169
   PubMed Web of Science ®Google Scholar
• Dai HR, Tong C, Shi DW, Chen MX, Guo YL, Chen DY, Han X, Wang H, Wang Y, Shen PP. Efficacy and biomarker analysis of CD133-directed CAR T cells in advanced hepatocellular carcinoma: a single-arm, open-label, phase II trial. Oncoimmunology. 2020;9(1):1846926. doi:10.1080/2162402x.2020.1846926.
   PubMed Web of Science ®Google Scholar
• Bach P, Abel T, Hoffmann C, Gal Z, Braun G, Voelker I, Ball CR, Johnston IC, Lauer UM, Herold-Mende C, et al. Specific elimination of CD133+ tumor cells with targeted oncolytic measles virus. Cancer Res. 2013;73(2):865–874. DOI:10.1158/0008-5472.Can-12-2221
   PubMed Web of Science ®Google Scholar
• Terai K, Bi DS, Liu Z, Kimura KG, Sanaat Z, Dolatkhah R, Soleimani M, Jones C, Bright A, Esfandyari T, et al. A novel oncolytic herpes capable of cell-specific transcriptional targeting of CD133± cancer cells induces significant tumor regression. Stem Cells. 2018;36(8):1154–1169. DOI:10.1002/stem.2835
   PubMed Web of Science ®Google Scholar
• Song Y, Jang J, Shin TH, Bae SM, Kim JS, Kim KM, Myung SJ, Choi Ek SHR, Seo HR. Sulfasalazine attenuates evading anticancer response of CD133-positive hepatocellular carcinoma cells. J Exp Clin Cancer Res. 2017;36(1):38. doi:10.1186/s13046-017-0511-7.
   PubMed Web of Science ®Google Scholar
• Song Y, Kim IK, Choi I, Kim SH, Seo HR. Oxytetracycline have the therapeutic efficiency in CD133(+) HCC population through suppression CD133 expression by decreasing of protein stability of CD133. Sci Rep. 2018;8(1):16100. doi:10.1038/s41598-018-34301-1.
   PubMedGoogle Scholar
• Ye JF, Sun D, Yu Y, Yu JH. Osthole resensitizes CD133(+) hepatocellular carcinoma cells to cisplatin treatment via PTEN/AKT pathway. Aging. 2020;12(14):14406–14417. doi:10.18632/aging.103484.
   PubMedGoogle Scholar
• Zhang KZ, Zhang QB, Zhang QB, Sun HC, Ao JY, Chai ZT, Zhu XD, Lu L, Zhang YY, Bu Y, et al. Arsenic trioxide induces differentiation of CD133+ hepatocellular carcinoma cells and prolongs posthepatectomy survival by targeting GLI1 expression in a mouse model. J Hematol Oncol. 2014;7:28. doi:10.1186/1756-8722-7-28.
   PubMed Web of Science ®Google Scholar
• Song Y, Kim S, Lee H, No JH, Ryu HC, Kim J, Lim JW, Kim M, Choi I, Seo HR. Chromenopyrimidinone controls stemness and malignancy by suppressing CD133 expression in hepatocellular carcinoma. Cancers. 2020;12(5):1193. doi:10.3390/cancers12051193.
   PubMed Web of Science ®Google Scholar